UNCY

Unicycive Therapeutics, Inc. (UNCY) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on kidney disease. Its primary product candidates are oxylanthanum carbonate (OLC) for hyperphosphatemia in chronic kidney disease (CKD) patients and UNI-494 for acute kidney injury (AKI). The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2026):

• Operating Activities: Net cash used of $13.8 million.
• Investing Activities: Net cash used of $5.2 million (primarily purchases of marketable securities).
• Financing Activities: Net cash provided of $34.0 million (primarily from an at-the-market offering).

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 147% to $14.5 million for the six-month period, driven by higher operating expenses ($18.6M vs $15.0M) and a decrease in non-cash gains from warrant liability revaluation ($3.2M gain vs $8.7M gain in the prior period).
• Expense Growth: General and Administrative (G&A) expenses rose 29% to $14.2 million, largely due to increased stock-based compensation ($1.6M increase) and professional fees. Research and Development (R&D) expenses increased 12% to $4.4 million.
• Liquidity Improvement: Cash and cash equivalents increased by $15.0 million to $44.2 million, bolstered by $34.0 million in net proceeds from the sale of common stock under a sales agreement with Guggenheim Securities.
• Warrant Liability: The fair value of the warrant liability decreased by $3.2 million during the period, recognized as a gain in other income.

Guidance, Outlook, and Risks

Regulatory Status: On June 30, 2026, the company received a second Complete Response Letter (CRL) from the FDA regarding the resubmitted NDA for oxylanthanum carbonate. The CRL cites the same third-party manufacturing deficiencies identified in a previous CRL issued in June 2025. The FDA noted no concerns regarding clinical efficacy or safety data.

Liquidity Outlook: Management believes current cash resources are sufficient to fund operations for at least 12 months from the filing date. However, the company expects to incur substantial additional losses and will require further capital to complete clinical trials and pursue commercialization.

Legal Proceedings: The company is facing a putative shareholder class action lawsuit (Elkhodari v. Unicycive Therapeutics, Inc.) and related derivative actions alleging misrepresentations regarding manufacturing and NDA approval prospects. The company intends to vigorously defend these claims but notes that defense costs could be material.

Risks: Key risks include the inability to resolve FDA manufacturing deficiencies, failure to secure additional financing, and the outcome of pending litigation.

Investor Verification Checklist

• FDA Resolution: Verify the specific steps taken to resolve the manufacturing deficiencies cited in the June 2026 CRL and the timeline for any potential resubmission.
• Cash Runway: Confirm the burn rate and the sufficiency of the $44.2 million cash balance given the recent regulatory setback and ongoing litigation costs.
• Warrant Liability Volatility: Monitor the fair value of the $13.7 million warrant liability, as changes in this non-cash item significantly impact reported net loss.
• Litigation Status: Track the progress of the securities class action and derivative suits, specifically the motion to dismiss filed by the company.
• Capital Raising: Assess the remaining capacity under the $150 million sales agreement with Guggenheim Securities and the potential for dilution in future equity offerings.